文献速递糖尿病

基于连续葡萄糖监测数据动力学的新型糖尿病检测与进展标志物

Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

研究利用843名1型糖尿病、2型糖尿病或健康个体的5754份每日连续葡萄糖监测(CGM)数据,计算CGM熵率(ER)和Poincaré图椭圆面积(S)两个动力学标志物。ER和S区分健康与糖尿病的AUC分别为0.98和0.99,区分1型与2型的AUC分别为0.81和0.76,区分1型糖尿病低与高免疫风险的AUC分别为0.72和0.66。作者认为CGM动力学标志物可作为空腹血糖或糖耐量试验的替代方法,识别进展为1型糖尿病免疫风险较高的个体。

要点

  • ER和S区分健康与糖尿病的AUC分别为0.98(95% CI,0.97-0.99)和0.99(95% CI,0.99-1.00)。
  • ER和S区分1型与2型糖尿病的AUC分别为0.81(95% CI,0.77-0.84)和0.76(95% CI,0.72-0.81)。
  • ER和S区分1型糖尿病低与高免疫风险的AUC分别为0.72(95% CI,0.58-0.86)和0.66(95% CI,0.47-0.86)。

核心结论

  • CGM动力学标志物可作为空腹血糖或糖耐量试验的替代方法,识别进展为1型糖尿病免疫风险较高的个体。

研究设计与样本

  • 研究使用来自843名1型糖尿病、2型糖尿病或健康个体(有或无胰岛自身抗体状态)的5754份每日CGM数据,计算ER和S两个个体动力学标志物。
  • 采用Youden指数确定ER和S在健康 vs 糖尿病(情况1)、1型 vs 2型(情况2)、1型低 vs 高免疫风险(情况3)中的「最佳」切点,并通过受试者工作特征曲线下面积(AUC)评估判别能力。

主要发现

  • 情况1(健康 vs 糖尿病):ER的AUC=0.98(95% CI,0.97-0.99),S的AUC=0.99(95% CI,0.99-1.00),切点分别为ERcase1=0.76 BPT、Scase1=1993.91 mg2/dL2。
  • 情况2(1型 vs 2型糖尿病):ER的AUC=0.81(95% CI,0.77-0.84),S的AUC=0.76(95% CI,0.72-0.81),切点分别为ERcase2=1.00 BPT、Scase2=5112.98 mg2/dL2。
  • 情况3(1型糖尿病低 vs 高免疫风险):ER的AUC=0.72(95% CI,0.58-0.86),S的AUC=0.66(95% CI,0.47-0.86),切点分别为ERcase3=0.52 BPT、Scase3=923.65 mg2/dL2。

关键数值与推荐

  • ER和S在健康 vs 糖尿病中的最佳切点分别为0.76 BPT和1993.91 mg2/dL2。
  • ER和S在1型 vs 2型糖尿病中的最佳切点分别为1.00 BPT和5112.98 mg2/dL2。
  • ER和S在1型糖尿病低 vs 高免疫风险中的最佳切点分别为0.52 BPT和923.65 mg2/dL2。

临床怎么用

  • 作者认为CGM动力学标志物可作为空腹血糖或糖耐量试验的替代方法,识别进展为1型糖尿病免疫风险较高的个体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Static measures of continuous glucose monitoring (CGM) data, such as time spent in specific glucose ranges (70-180 mg/dL or 70-140 mg/dL), do not fully capture the dynamic nature of blood glucose, particularly the subtle gradual deterioration of glycemic control over time in individuals with early-stage type 1 diabetes. OBJECTIVE: Develop a diabetes diagnostic tool based on 2 markers of CGM dynamics: CGM entropy rate (ER) and Poincaré plot (PP) ellipse area (S). METHODS: A total of 5754 daily CGM profiles from 843 individuals with type 1, type 2 diabetes, or healthy individuals with or without islet autoantibody status were used to compute 2 individual dynamic markers: ER (in bits per transition; BPT) of daily probability matrices describing CGM transitions between 8 glycemic states, and the area S (mg2/dL2) of individual CGM PP ellipses using standard PP descriptors. The Youden index was used to determine "optimal" cut-points for ER and S for health vs diabetes (case 1); type 1 vs type 2 (case 2); and low vs high type 1 immunological risk (case 3). The markers' discriminative power was assessed through the area under the receiver operating characteristics curves (AUC). RESULTS: Optimal cutoff points were determined for ER and S for each of the 3 cases. ER and S discriminated case 1 with AUC = 0.98 (95% CI, 0.97-0.99) and AUC = 0.99 (95% CI, 0.99-1.00), respectively (cutoffs ERcase1 = 0.76 BPT, Scase1 = 1993.91 mg2/dL2), case 2 with AUC = 0.81 (95% CI, 0.77-0.84) and AUC = 0.76 (95% CI, 0.72-0.81), respectively (ERcase2 = 1.00 BPT, Scase2 = 5112.98 mg2/dL2), and case 3 with AUC = 0.72 (95% CI, 0.58-0.86), and AUC = 0.66 (95% CI, 0.47-0.86), respectively (ERcase3 = 0.52 BPT, Scase3 = 923.65 mg2/dL2). CONCLUSION: CGM dynamics markers can be an alternative to fasting plasma glucose or glucose tolerance testing to identify individuals at higher immunological risk of progressing to type 1 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Montaser E, Farhy LS, Kovatchev BP, et al. Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics. J Clin Endocrinol Metab. 2024. PMID: 38820084. doi:10.1210/clinem/dgae379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。